Table 3.
Treatment and Outcome (n = 26)
| Treatment | Total (n = 26) | Non-survivors (n = 7) | Survivors (n = 19) | p-value |
|---|---|---|---|---|
| Management of immunosuppression | ||||
| Discontinuation of one or more immunosuppressors, n (%) | 9 (35) | 5 (71) | 4 (21) | 0.02 |
| Oral or intravenous steroids, n (%) | 14 (54) | 0 (0) | 14 (74) | <0.001 |
| Subgroup of patients with pneumonia (n = 17) | 8/17 (47) | 0/7 (0) | 8/10 (80) | <0.001 |
| Treatment of infection | ||||
| Enoxaparin, n (%) | 15 (58) | 7 (100) | 8 (42) | <0.01 |
| Hydroxychloroquine, n (%) | 18 (69) | 7 (100) | 11 (58) | 0.02 |
| Antibiotic therapy, n (%) | 22 (85) | 7 (100) | 15 (79) | 0.1 |
| Antiviral therapy, n (%) | 6 (23) | 6 (86) | 0 (0) | <0.001 |
| Intravenous steroids, n (%) | 7 (27) | 0 (0) | 7 (37) | 0.04 |
| Oxygen administration, n (%) | 16 (62) | 7 (100) | 9 (47) | <0.01 |
| CPAP, n (%) | 5 (19) | 5 (71) | 0 (0) | <0.001 |
| Outcomes | ||||
| Hospitalization, n (%) | 17 (65) | 7 (100) | 10 (53) | 0.01 |
| Hospitalization in ICU, n (%) | 5 (19) | 5 (71) | 0 (0) | <0.001 |
Abbreviations: CPAP, continuous positive airway pressure; ICU, intensive care unit.